TY - JOUR T1 - Preliminary Analysis of Excess Mortality in India During the Covid-19 Pandemic (Update September 26, 2021) JF - medRxiv DO - 10.1101/2021.08.04.21261604 SP - 2021.08.04.21261604 AU - Christopher T. Leffler AU - Joseph D. Lykins V AU - Edward Yang Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/27/2021.08.04.21261604.abstract N2 - As both testing for SARS Cov-2 and death registrations are incomplete or not yet available in many countries, the full impact of the Covid-19 pandemic is currently unknown in many world regions.We studied the Covid-19 and all-cause mortality in 19 Indian states (combined population of 1.27 billion) with available all-cause mortality data during the pandemic for the entire state or for large cities. Excess mortality was calculated by comparison with available data from years 2015-2019. The known Covid-19 deaths reported by the Johns Hopkins University Center for Systems Science and Engineering for a state were assumed to be accurate, unless excess mortality data suggested a higher toll during the pandemic. Data from one state were not included in the final model due to anomalies.In several regions, fewer deaths were reported in 2020 than expected. The excess mortality in Mumbai (in Maharashtra) in 2020 was 137.0 / 100K. Areas in Andhra Pradesh, Delhi, Haryana, Karnataka, Madhya Pradesh, Tamil Nadu, and Kolkata (in West Bengal), saw spikes in mortality in the spring of 2021.The pandemic-related mortality through August 31, 2021 in 18 Indian states was estimated to be 198.7 per 100,000 population (range 146.1 to 263.8 per 100K). If these rates apply to India as a whole, then 2.69 million people (range 1.98 to 3.57 million) may have perished in India as a result of the Covid-19 pandemic by August 31, 2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Virginia Commonwealth University Office of Research Subjects Protection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are in the appendix of the article. ER -